Mastología para médicos no mastólogos
Publicado
05 Enero 2026
Colección
Categorías
Derechos de autor 2026 Editorial Universidad de Boyacá
Detalles sobre esta monografía
ISBN-13
978-958-5120-75-4
Dimensiones físicas
Cómo citar
Camargo Villalba, G. E., Sánchez Capacho, N., & Castellanos Vega, R. del P. (2026). Mastología para médicos no mastólogos. Editorial Universidad de Boyacá. Recuperado a partir de https://libros.uniboyaca.edu.co/index.php/editorial-uniboyaca/catalog/book/118
Autores/as
https://orcid.org/0000-0003-4505-7644
Palabras clave:
Neoplasia de la mama
quiste mamario
densidad de la mama
mamografía
enfermedad fibroquística de la mama
diagnóstico clínico
estudio de validación
mama
Resumen
Si bien existen publicaciones previas sobre mastología, con temáticas que deben ser abordadas por médicos especializados en el área, fue necesario elaborar un libro con contenidos de abordaje y elementos claros y suficientes para los médicos generales, con el fin de facilitar la realización de una adecuada orientación clínica, diagnóstico, manejo y remisión oportuna.
Objetivo: Evaluar el contenido del libro Mastología para médicos no mastólogos a través del instrumento Texas Textbook Evaluation Tool (T-TET), realizar la adaptación y validación transcultural del instrumento de medición T-TET, y evaluar las características del contenido del libro para elaborar la segunda edición con base en los resultados identificados.
Metodología: Para el logro de la evaluación del libro, se realizó un proceso de adaptación y validación transcultural del T-TET con posterior revisión narrativa de cada capítulo incluido, basado en una estrategia de búsqueda fundamentada en palabras clave y utilización de diferentes boleanos, en un periodo de tiempo y en diferentes bases de datos científicas.
Resultados: Se obtuvo la validación del instrumento T-TET y el libro Mastología para médicos no mastólogos, evaluado, actualizado y coherente con los resultados de la evaluación de su contenido.
Descargas
Los datos de descargas todavía no están disponibles.
Referencias
Pardo C, De Vries E, Buitrago L, Gamboa Ó. Atlas de mortalidad por cáncer en Colombia. Cuarta edición. Inst Nac Cancerol [Internet].2017;1:124. https://www.cancer.gov.co/ATLAS_de_Mortalidad_por_cancer_en_Colombia.pdf
GLOBOCAN 2020, IARC, WHO. Breast Cancer incidence and mortality stadistics. GLOBOCAN 2020. 2020.
GLOBOCAN 2020, IARC, WHO. The Global Cancer Observatory - All cancers. GLOBOCAN 2020 [Internet]. 2020. https://gco.iarc.fr/today/home
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Scully O, Bay B-H, Yip G, Yu Y. Breast Cancer Metastasis. Adv Exp Med Biol. 2021;1187:183–204.
Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening [Internet]. Vol. 151, Progress in Molecular Biology and Translational Science. Elsevier Inc.; 2017;1–32. http://dx.doi.org/10.1016/bs.pmbts.2017.07.002
Taghian A, Merajver SD. Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer—UpToDate. 2021. https://www-uptodate-com.ezproxy.ums.edu.my/contents/overview-of-the-treatment-of-newly-diagnosed-invasive-non-metastatic-breast-cancersearch=breastcancer&source=search_result&selected Title=1~150&usage_type=default&display_rank=1#H29914106
Ruddy KJ, Partridge AH. Approach to the patient following treatment for breast cancer. 2014;1-18.
Bonnie N. Clinical features, diagnosis, and staging of newly diagnosed breast cancer - UpToDate. UpToDate [Internet]. 2018;8. https://www.uptodate.com/contents/clinical-features-diagnosis-and-staging-of-newly-diagnosed-breast-cancer?search=cáncerdemama&-sectionRank=2&usage_type=default&anchor=H1749806644&-source=machineLearning&selectedTitle=2~150&display_rank=2#H158324
Rojas K, Stuckey A. Breast Cancer Epidemiology and Risk Factors. 2016;59(4):651–72.
Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer [Internet]. 2020;20(8):417–36. http://dx.doi.org/10.1038/s41568-020-0266-x
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387–97.
Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):1–23.
Saito R, Miki Y, Hata S, Ishida T, Suzuki T. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Res Treat. 2017;161(3):399–407.
Gaudet HM, Christensen E, Conn B, Morrow S, Cressey L, Benoit J. Methylmercury promotes breast cancer cell proliferation. Toxicol Reports [Internet]. 2018;5(June 2017):579–84. https://doi.org/10.1016/j.toxrep.2018.05.002
Pullella K, Kotsopoulos J. Arsenic Exposure and Breast Cancer Risk: A Re-Evaluation of the Literature. 2020;1–17.
Barber LE, Zirpoli GR, Cozier YC, Rosenberg L, Petrick JL, Bertrand KA, et al. Neighborhood disadvantage and individual‑level life stressors in relation to breast cancer incidence in US Black women. Breast Cancer Res [Internet]. 2021;1–12. https://doi.org/10.1186/s13058-021-01483-y
Chishiki M, Takagi K, Sato A, Miki Y, Yamamoto Y, Ebata A, et al. Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. Cancer Sci. 2017;108(7):1510–9.
Watkins EJ. Overview of breast cancer. J Am Acad Physician Assist. 2019;32(10):13–7.
Solin LJ. Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. Curr Oncol Rep. 2019;21(4):19–26.
Badve S, Gökmen-Polar Y. Ductal carcinoma in situ of breast: update 2019. Physiol Behav. 2016;176(3):139–48.
Sisti A, Huayllani MT, Restrepo DJ, Boczar D, Advani P, Lu X, et al. Paget disease of the breast: A national retrospective analysis of the US population. Breast Dis. 2020;39(3-4):119–26.
Gilmore R, Prasath V, Habibi M. Paget disease of the breast in pregnancy and lactation. Adv Exp Med Biol. 2020;1252:133–6.
Feng CY, Zheng QL, Yang YH. Breast Microinvasive Carcinoma With Different Morphologies: Analysis of Clinicopathologic Features of 121 Cases. Breast Cancer Basic Clin Res. 2020;14:0–5.
Zhang H, Moisini I, Turner BM, Wang X, Dhakal A, Yang Q, et al. Significance of HER2 in Microinvasive Breast Carcinoma. Am J Clin Pathol. 2021;156(1):155–65.
Costarelli L, Cianchetti E, Corsi F, Friedman D, Ghilli M, Lacaria MT, et al. Microinvasive breast carcinoma: An analysis from ten Senonetwork Italia breast centres. Eur J Surg Oncol [Internet]. 2019;45(2):147–52. https://doi.org/10.1016/j.ejso.2018.09.024
Trøstrup H, Saltvig I, Matzen SH. Current surgical techniques for nipple reduction: A literature review. JPRAS Open. 2019;21:48–55.
Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020;112(1):25–41.
Kovacs T, Rubio IT, Markopoulos C, Audisio RA, Knox S, Kühn T, et al. Theoretical and practical knowledge curriculum for European Breast Surgeons. Eur J Surg Oncol. 2020;46(4):717–36.
Saadallah F, Bouraoui I, Naija L, Sakhri S, Zemni I, Hassouna J Ben, et al. Coexistence of invasive ductal breast carcinoma and fibroadenoma. Pan Afr Med J. 2019;33:1-4.
Metzger-Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, et al. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. Oncologist. 2019;24(7):e441–9.
Thomas M, Kelly ED, Abraham J, Kruse M. Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 2019;46(2):121-32. https://doi.org/10.1053/j.seminoncol.2019.03.002
Guo R, Chen B, Erickson LA. Mucinous Carcinoma of the Breast. Mayo Clin Proc. 2020;95(9):2049–50. https://doi.org/10.1016/j.mayocp.2020.07.008
Pintican R, Duma M, Chiorean A, Fetica B, Badan M, Bura V, et al. Mucinous versus medullary breast carcinoma: mammography, ultrasound, and MRI findings. Clin Radiol. 2020;75(7):483–96. https://doi.org/10.1016/j.crad.2019.12.024
Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, et al. Papillary carcinoma of the breast: An overview. Breast Cancer Res Treat. 2010;122(3):637-45.
Hashmi AA, Aijaz S, Mahboob R, Khan SM, Irfan M, Iftikhar N, et al. Clinicopathologic features of invasive metaplastic and micropapillary breast carcinoma: Comparison with invasive ductal carcinoma of breast. BMC Res Notes [Internet]. 2018;11(1):1–7. https://doi.org/10.1186/s13104-018-3623-z
Solanki MH, Derylo AF, Jorns JM. Invasive Mammary Carcinoma With Mixed Invasive Papillary and Glycogen Rich Clear Cell Features. Int JSurg Pathol. 2018;26(6):569–72.
Salemis NS, Mourtzoukou D. Encapsulated papillary carcinoma of the breast. Breast J. 2021;27(3):280–3.
Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79(August).
Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, et al. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am. 2018;98(4):787–800.
Piñeros M, Parkin DM, Ward K, Chokunonga E, Ervik M, Farrugia H, et al. Essential TNM: a registry tool to reduce gaps in cancer staging information. Lancet Oncol. 2019;20(2):e103–11. http://dx.doi.org/10.1016/S1470-045(18)30897-0
Hortobagyi GN, Edge SB, Giuliano A. New and Important Changes in the TNM Staging System for Breast Cancer. Am Soc Clin Oncol Educ B. 2018;(38):457–67.
Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Virchows Arch. 2018;472(5):697–703.
Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50. http://dx.doi.org/10.1016/S0140-6736 (16)31891-8
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84(April).
Cocco S, Leone A, Piezzo M, Caputo R, Lauro V Di, Rella F Di, et al. Targeting autophagy in breast cancer. Int J Mol Sci. 2020;21(21):1–22.
Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HCS, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer. 2018;18(1):1-13.
Wuerstlein R, Harbeck N. Neoadjuvant Therapy for HER2-positive Breast Cancer. Rev Recent Clin Trials. 2017;12(2):81-92.
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, et al. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):1-17.
Chen X, He C, Han D, Zhou M, Wang Q, Tian J, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: A systematic review and meta-analysis. Futur Oncol. 2017;13(9):843-57.
Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):1-10.
Ministerio de Salud y Protección Social Colombia. Guía de Práctica Clínica para tratamiento integral, seguimiento y rehabilitación del cáncer de mama. 2da edición. Guía No 19. 2017;(19):1-50. http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_500/GPC_cancer_mama/GPC_Ca_mama_Profesionales2aEd.pdf
